Tag Archive for: Acceleron Pharma

Merck’s blood vessel disorder therapy receives US FDA’s priority review

If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.

Read more
/by

Merck’s blood vessel disorder drug succeeds in late-stage study

,

Merck & Co said a therapy it gained through the drugmaker’s $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.

Read more
/by